Hostname: page-component-5c6d5d7d68-wpx84 Total loading time: 0 Render date: 2024-08-16T11:48:38.150Z Has data issue: false hasContentIssue false

Clinical Culture Surveillance of Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter Species in a Teaching Hospital in São Paulo, Brazil: A 7-Year Study

Published online by Cambridge University Press:  21 June 2016

Guilherme Henrique Campos Furtado*
Affiliation:
Infection Control Committee, Division of Infectious Diseases, Federal University of São Paulo, São Paulo, Brazil
Sinaida Teixeira Martins
Affiliation:
Infection Control Committee, Division of Infectious Diseases, Federal University of São Paulo, São Paulo, Brazil
Antônia Maria Oliveira Machado
Affiliation:
Microbiology Laboratory, São Paulo Hospital, Federal University of São Paulo, São Paulo, Brazil
Sérgio Barsanti Wey
Affiliation:
Infection Control Committee, Division of Infectious Diseases, Federal University of São Paulo, São Paulo, Brazil
Eduardo Alexandrino Servolo Medeiros
Affiliation:
Infection Control Committee, Division of Infectious Diseases, Federal University of São Paulo, São Paulo, Brazil
*
R. Dr. Diogo de Faria, 1226 Apartment 102, Vila Clementino, 04037-004 São Paulo-SP, Brazil (ghfurtado@uol.com.br)

Abstract

Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species are worrisome nosocomial pathogens. After introduction of a preventive program involving clinical surveillance culture to reduce the spread of those pathogens, we observed an 80% decrease in the percentage of cultures that yielded carbapenem-resistant Acinetobacter isolates. The percentage of cultures that yielded carbapenem-resistant P. aeruginosa remained relatively stable during the intervention.

Type
Concise Communications
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Shlaes, DM, Gerding, DN, John, JF, et al. Guidelines for the prevention of antimicrobial resistance in hospitals. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Infect Control Hosp Epidemiol 1997; 18:275291.CrossRefGoogle ScholarPubMed
2. Obritsch, MD, Fish, DN, MacLaren, R, Jung, R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrobial Agents Chemother 2004; 48:46064610.CrossRefGoogle ScholarPubMed
3. Andrade, SS, Jones, RN, Gales, AC, Jones, RN, Sader, HS. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centers: 5-year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother 2003; 52:140141.CrossRefGoogle Scholar
4. Sader, HS. Antimicrobial resistance in Brazil: comparison of results from two multicenter studies. Braz J Infect Dis 2000; 4:9199.Google ScholarPubMed
5. Leppeletier, D, Perron, S, Huguenin, H, et al. Which strategies follow from the surveillance of multidrug-resistant bacteria to strengthen the control of their spread? A French experience. Infect Control Hosp Epidemiol 2004; 25:162164.CrossRefGoogle Scholar
6. Bonten, MJM, Bergmans, DCJJ, Speijer, H, Stobberingh, EE. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Am J Respir Crit Care Med 1999; 160:12121219.CrossRefGoogle ScholarPubMed
7. Sader, HS, Reis, AO, Silbert, S, Gales, AC. IMPs, VIMs and SPMs: the diversity of metallo-β-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital. Clin Microbiol Infect 2005; 11:7376.CrossRefGoogle Scholar
8. Zavascki, AP, Cruz, RP, Goldani, LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005; 59:96101.CrossRefGoogle ScholarPubMed
9. Mutnick, AH, Rhomberg, PR, Sader, HS, Jones, RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004; 53:290296.CrossRefGoogle ScholarPubMed
10. Gales, AC, Tognim, MC, Reis, AO, Jones, RN, Sader, HS. Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis 2003; 45:7779.CrossRefGoogle Scholar
11. Sunenshine, RH, Liedtke, LA, Fridkin, SK, Strausbaugh, LJ. Management of inpatients colonized or infected with antimicrobial-resistant bacteria in hospitals in the United States. The Infectious Diseases Society of America Emerging Infectious Network. Infect Control Hosp Epidemiol 2005; 26:138143.CrossRefGoogle ScholarPubMed